Navigation Links
Caelyx Delays Time to Disease Progression as Maintenance Therapy in,Patients with Metastatic Breast Cancer

CHICAGO - June 3, 2007 - Schering-Plough Corp. announced results from a Phase III study that showed maintenance chemotherapy with Caelyx (pegylated liposomal doxorubicin hydrochloride) significantly prolonged time to progression (TTP) in patients with metastatic breast cancer with infrequent and manageable clinical toxicity after first-line chemotherapy. These data were presented today at the 43rd Annual Meeting of the American Society of Clinical Oncology.

"While standard chemotherapy has proven effective for patients with metastatic breast cancer, their response is short-lived and the time to progression is brief," said Emilio Alba, M.D., professor at Hospital U. Virgen de la Victoria, in Malaga, Spain and lead investigator for the
study. "The results from this study showed a significantly improved time to progression (13.2 months) in patients treated with CAELYX versus the observational arm (10.2 months)."
The Spanish Cooperative Group, Grupo Espanol de Investigacion en Cancer de Mama (GEICAM) conducted the multi-center, Phase III study at seven different sites throughout Spain.

Of the 288 patients with metastatic breast cancer registered for the trial, 155 subjects who had responded to initial therapy or had stable disease were randomized either to receive CAELYX or to observation. Patients receiving therapy were given a regimen of CAELYX at 40 mg/m2 once every four weeks for 6 cycles of therapy. Patients in the CAELYX arm experienced a median improvement in time to progression of three months (13.2 months versus the observational arm of 10.2 months; p=0.0005).

The patients in the study had a median age of 57, and had adequate bone marrow, renal, hepatic and cardiac function. These patients had experienced either complete response, partial response or had stable disease. Patients received induction chemotherapy with three cycles of
anthracycline followed by three cycles of taxane, and were then randoml
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Appendicitis: Evolving Tools to Diagnose a Classic Disease
2. Non-Invasive Diagnostic Tests for Celiac Disease
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
5. Samaritans Alzheimers Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimers Disease
6. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
7. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
8. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
9. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
10. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
11. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
Post Your Comments:
(Date:3/2/2015)... SOUTH SAN FRANCISCO, Calif. , March 2, ... therapeutics for the treatment of cancer, today announced ... comprised of leading researchers and clinicians in the ... The new advisory boards will ... its wholly owned pipeline of precision immunotherapies and ...
(Date:3/2/2015)... , March 2, 2015   Mast ... biopharmaceutical company, today announced preliminary findings from a ... a model of chronic, stable heart failure produced ... study was to examine the effects of repeat ... systolic and diastolic function. Consistent ...
(Date:3/2/2015)... 2015  Delcath Systems, Inc. (NASDAQ: DCTH ... on oncology with an emphasis on the treatment of ... will participate in the upcoming 27 th Annual ... the Ritz Carlton Laguna Niguel in Dana ... MSN, CRNP, Delcath,s interim President and Chief Executive Officer, ...
Breaking Medicine Technology:CytomX Expands Scientific and Clinical Advisory Boards with Leading Experts in Cancer Immunotherapy and Antibody Drug Conjugates 2CytomX Expands Scientific and Clinical Advisory Boards with Leading Experts in Cancer Immunotherapy and Antibody Drug Conjugates 3Mast Announces Results From Nonclinical Study Investigating Repeat Treatment With Vepoloxamer In Advanced Heart Failure 2Mast Announces Results From Nonclinical Study Investigating Repeat Treatment With Vepoloxamer In Advanced Heart Failure 3Mast Announces Results From Nonclinical Study Investigating Repeat Treatment With Vepoloxamer In Advanced Heart Failure 4Mast Announces Results From Nonclinical Study Investigating Repeat Treatment With Vepoloxamer In Advanced Heart Failure 5Mast Announces Results From Nonclinical Study Investigating Repeat Treatment With Vepoloxamer In Advanced Heart Failure 6Delcath To Present At The 27th Annual Roth Conference 2Delcath To Present At The 27th Annual Roth Conference 3
... The Epilepsy Foundation recently announced findings that show ... a consistent drug therapy, have a greater chance of ... their medications are switched from one version of an ... brand-to-generic, generic-to-brand or generic-to-generic. See video from the Epilepsy ...
... Findings Reinforce March of Dimes Message: Start Taking a ... 11 Women who take folic acid supplements for ... cut their risk of having a premature baby by ... online journal, PLOS Medicine.The study links pre-conceptional folate supplementation ...
Cached Medicine Technology:VIDEO from Medialink and the Epilepsy Foundation: New Study Suggests Different Versions of the Same Epilepsy Medication Can Be Harmful 2Taking Folic Acid for a Year Before Pregnancy May Reduce Risk of Preterm Birth 2
(Date:3/2/2015)... 02, 2015 LegitScript, LLC, ... certification programs, including those for Internet pharmacy ... safety and classification, has launched a certification ... The new program, called iCareRx , ... regarding the identity of the owner/operator of ...
(Date:3/2/2015)... 02, 2015 Regulatory Compliance Associates® ... quality, regulatory and technical consulting, announces Mr. Seyed ... Officer. , Before joining RCA, Mr. Khorashahi ... teams in all aspects of developing safety-critical medical ... Covidien (Medtronic), Regulatory Compliance Associates Inc., Baxter Healthcare, ...
(Date:3/2/2015)... 02, 2015 The Alliance for Bangladesh ... expert Mark Chubb to serve as chief safety officer. ... and training in Bangladesh and guide remediation efforts in ... “Mark will ensure that the Alliance continues to bring ... for Bangladesh garment workers,” said Alliance Independent Chair Ellen ...
(Date:3/2/2015)... 2015 Final Cut Pro X ... 2 from Pixel Film Studios. , “The TranStatic Volume 2 ... said Christina Austin, CEO of Pixel Film Studios. “TranStatic Volume ... Cut Pro X editors toolbox.” , With TranStatic Volume 2 ... media altering static scrambling effects from Pixel Film Studios. Users ...
(Date:3/1/2015)... As residents and business owners in ... and Carita Weaver, believe in supporting local organizations ... Southlake Chamber of Commerce, Carroll Independent School District ... a website for Southlake mayoral candidate Laura Hill: ... for Hill’s campaign, the website combines images, videos ...
Breaking Medicine News(10 mins):Health News:LegitScript Launches Certification Program for Internet Eyeglass Sellers 2Health News:Regulatory Compliance Associates® Inc. Welcomes Seyed Khorashahi as Chief Operating Officer 2Health News:Alliance for Bangladesh Worker Safety Names New Chief Safety Officer 2Health News:Pixel Film Studios released the TranStatic Volume 2 plugin for Final Cut Pro X today 2Health News:Website Launched for Southlake, Texas Mayoral Candidate Laura Hill 2
... older women with breast cancer lag behind younger women diagnosed ... missing out on improvements in treatment and detection, according to ... Center. The study, published in the Journal of ... whether the improvements made in breast cancer outcomes over the ...
... 2011) AMRI (NASDAQ: AMRI) announced today that, as ... and Company, it anticipates hiring more than 40 synthetic ... Lilly,s drug discovery programs. The chemists will work onsite ... support the medicinal chemistry department. This collaboration will ...
... Jenifer Goodwin HealthDay Reporter , MONDAY, Nov. ... child with autism or with a milder form of ... only by the child,s symptoms, but by where the ... found wide variability at autism centers across the nation ...
... CA The University of California, Santa Barbara ... Grand Challenges Explorations, an initiative created by the ... worldwide to test unorthodox ideas that address persistent ... Amr El Abbadi in the Computer Science Department ...
... The Lymphoma Division of the John Theurer Cancer Center at ... groups "Hope for Lymphoma" and "Our MCL Family," will host ... from 8:30am 3:45pm. The event is open to ... patients and their caregivers coping with this challenging diagnosis. ...
... HealthDay Reporter , SUNDAY, Nov. 6 (HealthDay News) -- ... the holiday season for some. For others, those airborne ... and sneezing to asthma attacks. Allergists say as ... complaints from their patients about reactions to them. ...
Cached Medicine News:Health News:UT MD Anderson study finds advances in breast cancer don't extend to older women 2Health News:UT MD Anderson study finds advances in breast cancer don't extend to older women 3Health News:Where a Child Is Tested May Affect Autism Diagnosis 2Health News:Where a Child Is Tested May Affect Autism Diagnosis 3Health News:UC Santa Barbara receives Grand Challenges Explorations funding 2Health News:UC Santa Barbara receives Grand Challenges Explorations funding 3Health News:John Theurer Cancer Center to host inaugural Mantle Cell Lymphoma Symposium 2Health News:John Theurer Cancer Center to host inaugural Mantle Cell Lymphoma Symposium 3Health News:Air Fresheners, Scented Candles May Spur Allergic Reactions 2Health News:Air Fresheners, Scented Candles May Spur Allergic Reactions 3
Portex® Blue Line® cuffed endotracheal tubes come in a wide selection of sizes, each with a standard 15 mm ISO connector., ,Portex® Blue Line® endotracheal tubes are recognized world...
Ruschelit® PVC. Murphy eye-nasoral. X-ray opaque line. Graduated. Single use. Sterile...
Ruschelit® PVC. Magill tip - nasoral. X-ray opaque line. Graduated. Single use. Sterile...
... Tube with stylet inside. Sterile, Latex ... Rusch endotracheal tube with a preloaded ... saving you time and storage space. ... easy identification and has a stopper ...
Medicine Products: